<SEC-DOCUMENT>0001104659-17-010092-index.html : 20170217 <SEC-HEADER>0001104659-17-010092.hdr.sgml : 20170217 <ACCEPTANCE-DATETIME>20170217104221 ACCESSION NUMBER: 0001104659-17-010092 CONFORMED SUBMISSION TYPE: POSASR PUBLIC DOCUMENT COUNT: 9 FILED AS OF DATE: 20170217 DATE AS OF CHANGE: 20170217 EFFECTIVENESS DATE: 20170217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVARTIS AG CENTRAL INDEX KEY: 0001114448 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: POSASR SEC ACT: 1933 Act SEC FILE NUMBER: 333-207004 FILM NUMBER: 17620168 BUSINESS ADDRESS: STREET 1: LICHTSTRASSE 35 CITY: BASEL STATE: V8 ZIP: CH 4056 BUSINESS PHONE: 01141613241111 MAIL ADDRESS: STREET 1: LICHTSTRASSE 35 CITY: BASEL STATE: V8 ZIP: CH 4056 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Novartis Capital CORP CENTRAL INDEX KEY: 0001443411 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263086456 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: POSASR SEC ACT: 1933 Act SEC FILE NUMBER: 333-207004-02 FILM NUMBER: 17620169 BUSINESS ADDRESS: STREET 1: 608 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: (212)307 1122 MAIL ADDRESS: STREET 1: 608 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10020 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Novartis Securities Investment Ltd. CENTRAL INDEX KEY: 0001443663 IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: POSASR SEC ACT: 1933 Act SEC FILE NUMBER: 333-207004-01 FILM NUMBER: 17620170 BUSINESS ADDRESS: STREET 1: 131 FRONT STREET CITY: HAMILTON STATE: D0 ZIP: HM 12 BUSINESS PHONE: (1)441 296 8025 MAIL ADDRESS: STREET 1: P.O.BOX HM 2899 CITY: HAMILTON STATE: D0 ZIP: HM LX </SEC-HEADER> <DOCUMENT> <TYPE>POSASR <SEQUENCE>1 <FILENAME>a17-4530_1posasr.htm <DESCRIPTION>POST-EFFECTIVE AMENDMENT NO.2 <TEXT> Document 1 - file: a17-4530_1posasr.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-4.6 <SEQUENCE>2 <FILENAME>a17-4530_1ex4d6.htm <DESCRIPTION>FORM OF GUARANTEED DEBT SECURITY FOR 1.800% NOTES DUE 2020 <TEXT> Document 2 - file: a17-4530_1ex4d6.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-4.7 <SEQUENCE>3 <FILENAME>a17-4530_1ex4d7.htm <DESCRIPTION>FORM OF GUARANTEED DEBT SECURITY FOR 2.400% NOTES DUE 2022 <TEXT> Document 3 - file: a17-4530_1ex4d7.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-4.8 <SEQUENCE>4 <FILENAME>a17-4530_1ex4d8.htm <DESCRIPTION>FORM OF GUARANTEED DEBT SECURITY FOR 3.100% NOTES DUE 2027 <TEXT> Document 4 - file: a17-4530_1ex4d8.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-4.9 <SEQUENCE>5 <FILENAME>a17-4530_1ex4d9.htm <DESCRIPTION>OFFICER'S CERTIFICATE OF NOVARTIS CAPITAL CORPORATION <TEXT> Document 5 - file: a17-4530_1ex4d9.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-5.6 <SEQUENCE>6 <FILENAME>a17-4530_1ex5d6.htm <DESCRIPTION>OPINION OF MAYER BROWN INTERNATIONAL LLP <TEXT> Document 6 - file: a17-4530_1ex5d6.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-5.7 <SEQUENCE>7 <FILENAME>a17-4530_1ex5d7.htm <DESCRIPTION>OPINION OF BAER & KARRER AG <TEXT> Document 7 - file: a17-4530_1ex5d7.htm
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>8 <FILENAME>g45301ksi001.gif <DESCRIPTION>GRAPHIC <TEXT> Document 8 - file: g45301ksi001.gif
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>9 <FILENAME>g45301kui001.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 9 - file: g45301kui001.jpg
</DOCUMENT> </SEC-DOCUMENT>